在UEG周的2024研究表明,使用ReCET与半谷氨酸治疗的T2D患者的胰岛素依赖性减少了86%,保持血糖控制并计划进行更大的试验. 2024 study at UEG Week demonstrates 86% reduction in insulin dependency for T2D patients using ReCET with semaglutide, maintaining glycaemic control and planning larger trials.
UEG 2024周提出的一项研究表明,对2型糖尿病(T2D)的新治疗可能减少或消除胰岛素依赖性。 A study presented at UEG Week 2024 indicates a new treatment for type 2 diabetes (T2D) that may reduce or eliminate insulin dependency. 将 ReCET（通过电穿孔疗法重新细胞化）与 semaglutide 相结合，14 名参与者中有 86% 在 24 个月后不再需要胰岛素，同时保持血糖控制，没有严重的副作用。 Combining ReCET (Re-Cellularization via Electroporation Therapy) with semaglutide, 86% of 14 participants no longer needed insulin after 24 months, while maintaining glycaemic control without serious side effects. 研究人员计划进行更大的试验,以进一步验证这些有希望的成果。 Researchers plan to conduct larger trials to further validate these promising results.